Bigfoot Biomedical said today that it inked a non-exclusive deal with Eli Lilly (NYSE:LLY) to integrate Eli Lilly’s insulin products into Bigfoot’s investigational insulin delivery devices. The California-based company expects to launch its first two insulin delivery systems – Bigfoot Inject and Bigfoot Loop – in 2020, contingent upon finishing a pivotal trial and landing regulatory […]
How Bigfoot Biomedical’s CEO wants to boost diabetes management
Jeffrey Brewer faced the biggest challenge of his life when his 7-year-old son Sean received a diabetes diagnosis in 2002: Diabetes became the new focus for Brewer’s energy. In his role as CEO at JDRF (formerly the Juvenile Diabetes Research Foundation) between 2011 and 2014, Brewer forged financial partnerships with industry to drive the development […]
Bigfoot brings Series B total to $55m with new investment from Abbott
Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the […]
SFC Fluidics inks deal with JDRF to develop automated insulin delivery system
SFC Fluidics has inked a two-year deal with JDRF to develop an automated insulin delivery system that combines a continuous glucose monitor and an insulin delivery algorithm into a single disposable device. JDRF is slated to provide funding to the medical device company as part of its Artificial Pancreas Project, which aims to accelerate the […]
Bigfoot Biomedical raises $37m in Series B
Bigfoot Biomedical said today that it has raised $37 million in the first tranche of a Series B round, co-led by new investor Janus Henderson Investors and the company’s largest existing investor, Quadrant Capital Advisors. The Milpitas, Calif.-based company plans to use its newly-acquired funds to support product development and clinical evaluation of its automated […]
Bigfoot Biomedical CEO hits back against CMS over data-sharing decision
Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has […]
Bigfoot compares trial data with modeling results for automated insulin delivery system
Bigfoot Biomedical touted data last week at this year’s Diabetes Technology Meeting showing that results from a feasibility study evaluating the company’s automated insulin delivery system closely matched data gleaned from prospective modeling. The company said it conducted extensive modeling to refine the technology’s algorithms prior to the start of its trial in 2016, Bigfoot […]
Ypsomed to supply Bigfoot with insulin infusion sets for pivotal trial
Ypsomed plans to supply Bigfoot Biomedical with a modified version of its Orbit infusion set for the pivotal trial of Bigfoot’s automated insulin delivery system, the companies said today. Ypsomed’s Orbit infusion sets can be rotated 360°, giving users the freedom to move around, and are fitted using a heat-activated patch. The infusion sets are available with steel or […]
Here’s how the diabetes industry’s leaders think about patient-centered R&D
Designing devices centered around patients is a goal espoused by nearly all device companies nowadays, as they aim to make products that people want to use and can incorporate into their everyday lives. Underscoring those products is often years of research and some in the industry have begun to think about how a patient’s needs […]
Why Bigfoot Biomedical’s CEO thinks the diabetes industry has a data problem
Bigfoot Biomedical‘s chief executive is excited about Abbott‘s (NYSE:ABT) latest regulatory win – and it’s not just because the two companies have an established partnership. Yesterday, the FDA approved Abbott’s FreeStyle Libre Flash continuous glucose monitoring system. It’s the first device of its kind, allowing patients to track their blood glucose levels without the use […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn